Investment Rating - The report maintains a "Buy" rating for the company [8] Core Views - The blood products business shows steady growth, with a continuous expansion of the product lineup [6] - The company has adjusted its net profit forecasts for 2024 and 2025 to CNY 5.51 billion and CNY 6.02 billion, respectively, down by 20% and 26% from previous estimates [4][5] - The projected net profit for 2026 is CNY 6.56 billion, representing a year-on-year growth of 132.11% [4] Financial Summary - The company reported a revenue of CNY 26.52 billion in 2023, a decrease of 3.87% year-on-year [4] - The net profit attributable to the parent company was CNY 2.37 billion, down 45.06% year-on-year [4] - The basic EPS for 2023 was CNY 0.47, with forecasts for 2024, 2025, and 2026 at CNY 1.09, CNY 1.19, and CNY 1.30, respectively [4][5] - The company’s blood products revenue reached CNY 14.52 billion in 2023, an increase of 10.41% year-on-year [5] - The company has 16 plasma collection stations, with 14 currently operational, and collected approximately 467.3 tons of raw plasma in 2023, up 6.47% year-on-year [5] Product Development - The company received approval for clinical trials of its C1 esterase inhibitor, accelerating the progress of its research and development projects [6] - Ongoing clinical studies for von Willebrand factor and intravenous immunoglobulin (IVIG) are expected to expedite production approvals [6]

华润博雅生物制药集团股份有限公司（以下简称公司）接控股股东华润医药 控股有限公司(以下简称华润医药控股)通知，华润医药控股的控股股东华润医药 集团有限公司(以下简称华润医药集团) 于 2024 年 3 月 26 日在香港联合交易所 有限公司(以下简称香港联交所)刊发了 2023 年业绩公告。 投资者如需了解华润医药集团 2023 年业绩公告的详细信息，请查询香港联 交所网站：http://www.hkexnews.hk。 特此公告。 证券代码：300294 证券简称：博雅生物 公告编号：2024-036 华润博雅生物制药集团股份有限公司 关于控股股东之控股股东华润医药集团有限公司 刊发 2023 年业绩公告的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 华润博雅生物制药集团股份有限公司董事会 2024 年 3 月 26 日 ...

证券代码：300294 证券简称：博雅生物 公告编号：2024-034 华润博雅生物制药集团股份有限公司 关于召开 2023 年度股东大会的通知更正公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 华润博雅生物制药集团股份有限公司（以下简称公司）于 2024 年 3 月 23 日在巨潮资讯网披露了《关于召开 2023 年度股东大会的通知》，经事后核查， 发现由于工作人员的疏忽，导致《关于召开 2023 年度股东大会的通知》内容有 误。公告中 附件 1"二、通过深交所交易系统投票的程序""三、通过深交所 互联网投票系统投票的程序"中的"投票时间"有误，现作如下更正： 更正前： 二、通过深交所交易系统投票的程序 1、投票时间：2024 年 4 月 8 日的交易时间，即 9:15-9:25,9:30-11:30 和 13:00-15:00。 2、股东可以登录证券公司交易客户端通过交易系统投票。 二、通过深交所交易系统投票的程序 1、投票时间：2024 年 4 月 12 日的交易时间，即 9:15-9:25,9:30-11:30 和 13:00-15:00。 2、股东可 ...

证券代码：300294 证券简称：博雅生物 公告编号：2024-035 华润博雅生物制药集团股份有限公司 关于召开 2023 年度股东大会的通知（更新后） 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、召开会议基本情况 （一）大会届次：2023 年年度股东大会。 （二）会议召集人：公司董事会。（经公司第八届董事会第二次会议审议通 过，决定召开本次股东大会） （三）会议召开的合法、合规性：召集程序符合有关法律、行政法规、部门 规章、规范性文件和《公司章程》的规定。 （四）会议召开时间：2024 年 4 月 12 日上午 09:30。 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2024 年 4 月 12 日上午 9:15-9:25，9:30-11:30，下午 13:00—15:00；通过互联网投票系 统投票的时间为 2024 年 4 月 12 日上午 9：15—下午 15:00 期间的任意时间。 （五）会议召开方式：现场投票和网络投票相结合的方式。 现场投票：股东本人出席现场会议或通过授权委托书（见附件 2）委托他人 出席； 网络投票：公司将通 ...

Board and Management Changes - The company held the 29th meeting of the 7th Board of Directors on March 4, 2024, approving the election of candidates for the 8th Board of Directors, including Mr. Qiu Kai and Mr. Liang Xiaoming as non-independent directors[1]. - The term of the independent directors Mr. Zhang Weidong, Mr. Zhao Li, and Mr. Huang Huasheng will end on February 2, 2027[2]. - The company elected Mr. Rao Zhen as the employee representative supervisor during the 6th meeting of the 6th Employee Representative Assembly on March 11, 2024[1]. - The 8th Board of Directors held its first meeting on March 21, 2024, where it approved the election of the chairman and the appointment of senior management personnel[1]. - The company has experienced changes in its board and management personnel, with several new appointments effective from October 25, 2023[5]. - The new board members include Mr. Qiu Kai as Chairman and Mr. Liang Xiaoming as President, both with extensive backgrounds in the pharmaceutical industry[6]. - The company is expanding its governance structure with the election of independent directors and supervisors to enhance oversight and compliance[2]. - The company’s leadership changes are aimed at driving future growth and innovation in the pharmaceutical sector[6]. Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 1.2 billion for the fiscal year 2023, representing a year-on-year growth of 15%[146]. - The company's operating revenue for 2023 was ¥2,651,979,506.66, a decrease of 3.87% compared to ¥2,758,701,315.10 in 2022[154]. - The net profit attributable to shareholders for 2023 was ¥237,465,593.87, down 45.06% from ¥432,197,553.97 in 2022[154]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥143,075,746.77, a decline of 63.51% compared to ¥392,124,538.69 in 2022[154]. - The gross margin for the year was reported at 45%, a slight decrease from 48% in the previous year, attributed to increased raw material costs[146]. - The company reported a loss of CNY 3,894.56 million from the transfer of 89.681% equity of Guizhou Tianan Pharmaceutical Co., Ltd.[126]. - The company reported a net profit loss in the fourth quarter primarily due to a goodwill impairment provision of CNY 298.41 million related to the acquisition of Nanjing Xinbai Pharmaceutical Co., Ltd.[186]. Compliance and Governance - The company is committed to maintaining compliance with the regulations regarding independent directors, ensuring governance best practices[2]. - The company has received regulatory measures from the China Securities Regulatory Commission for information disclosure violations, which have been recorded in the integrity archives[15]. - The company is committed to ensuring the legality of economic contracts and major investment decisions, with a 100% legal review of important regulations and contracts[30]. - The internal control system has been strengthened, with timely reviews and updates to internal control procedures across various business areas, ensuring effective implementation[29]. - The company has reported no significant internal control deficiencies during the reporting period, indicating a robust internal control environment[33]. - The company has no violations or rectification situations during the reporting period[117]. - The company maintains a good integrity status for itself and its controlling shareholders[118]. Marketing and Strategic Focus - The company aims to enhance plasma station management capabilities, focusing on cost control and establishing benchmark stations to promote internal growth[20]. - The company plans to implement marketing reforms by adopting a refined招商 business model and building its own sales team to improve channel control and brand influence[22]. - The company is focused on increasing plasma collection volume by enhancing brand marketing and emotional engagement with donors[20]. - The company has a strategic focus on leveraging cornerstone products to drive sales and improve marketing effectiveness through targeted strategies[22]. - The company is accelerating marketing transformation and restructuring its marketing model to enhance management capabilities and focus on terminal hospital development and pure sales management[23]. - The company aims to increase market share by implementing targeted marketing strategies for core products such as pituitary posterior lobe, oxytocin, and bone peptide tablets, with a focus on developing blank areas[23]. Research and Development - The company is enhancing its innovative R&D capabilities by introducing or developing new products and activating the commercial value of dormant varieties to accelerate project sales[25]. - The company acknowledges that the development and launch of new blood products involve a lengthy and high-risk process, requiring significant resources and funding[24]. - Research and development expenses increased by 25% to RMB 150 million, reflecting the company's commitment to innovation[146]. - The company has established strategic partnerships with two leading research institutions to accelerate the development of new therapies[146]. - The company is actively developing new products, including a novel immunoglobulin therapy expected to enter clinical trials in Q2 2024[146]. Environmental Compliance - Huaren Boya Bio's existing projects have passed environmental impact assessments and obtained valid discharge permits[41]. - The company reported a COD level of 81.220 mg/L, which is below the national standard of 220 mg/L, with a total discharge of 4.885 tons[46]. - New Bai Pharmaceutical's gas emissions for non-methane total hydrocarbons were recorded at 0.49 mg/m³, significantly below the standard of 4 mg/m³[46]. - The company has received environmental impact report approvals for multiple construction projects, ensuring compliance with environmental regulations[41]. - The company has implemented pollution prevention measures in accordance with the environmental impact reports for its construction projects[40]. - The company has established a comprehensive pollution prevention and control system, ensuring compliance with environmental regulations[58]. - The company has implemented an automatic monitoring system for VOCs, which will enable real-time monitoring of volatile organic compounds after installation[63]. Social Responsibility - The company has invested a total of 2.62 million yuan in poverty alleviation efforts, focusing on improving educational resources in impoverished areas[82]. - The company allocated 150,000 yuan towards healthcare resources in impoverished regions as part of its poverty alleviation initiatives[85]. - The company has implemented a comprehensive employment strategy that promotes equal opportunities and adheres to labor laws, ensuring fair treatment of all employees[73]. Related Party Transactions - The total amount of related party transactions with China Resources Pharmaceutical Holdings and its affiliates reached CNY 29,636.92 million, accounting for 9.91% of similar transactions[121]. - The company sold 75% equity of Guangdong Fuda Pharmaceutical Co., Ltd. for CNY 36,476.42 million, resulting in a profit of CNY 3,427.62 million[123]. - The company has approved a transaction limit of CNY 31,320.00 million for related party transactions, which was not exceeded[121]. - The company reported a significant increase in user data, with a year-over-year growth of 29.34% in purchasing goods from related parties[121]. - The company has no significant related party transactions or loans during the reporting period[158][159]. Market Outlook - Looking ahead, the company projects a revenue growth of 10% for 2024, targeting RMB 1.32 billion in total revenue[146]. - The blood products industry is expected to maintain a stable growth trend due to the increasing demand for products like immunoglobulin and the stable pricing system established in the Beijing-Tianjin-Hebei region[200]. - By 2027, the Chinese blood products market is expected to reach CNY 78 billion, with a compound annual growth rate (CAGR) of 11.6% from 2022 to 2027[196]. - The number of newly operational plasma stations in China in 2023 was 33, indicating an acceleration in industry consolidation[196].

华润博雅生物制药集团股份有限公司 2023 年度非经营性资金占用及其他关联资金往来情况汇总表 金额单位：万元 | 非经营性资金占用 | 资金占用方 | | 占用方与上市 | 上市公司 | 2023 年期初 | | 2023 年度占用 累计发生金额 | 2023 | 年度占用 资金的利息 | | 2023 | 年度偿还 | 2023 | 年期末 | | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 名称 | | 公司的关联关系 | 核算的会计科目 | 占用资金余额 | | | | | | 累计发生金额 | | | 占用资金余额 | | | | | | | | | | | | (不含利息) | | (如有) | | | | | | | | | | 控股股东、实际控制人 及其附属企业 | | 无 | 不适用 | 不适用 | | - | | - | | - | | - | | | - | 不适用 | 不适用 ...

关于对会计师事务所2023年度履职情况评估报告及审计委员会对会 计师事务所履行监督职责的情况报告 华润博雅生物制药集团股份有限公司 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上 市公司自律监管指引第2号——创业板板上市公司规范运作》和华润博雅生物制 药集团股份有限公司（以下简称公司）的《公司章程》《董事会审计委员会工作 细则》等规定和要求，董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真 履职。现将董事会审计委员会对会计师事务所2023年度履职评估及履行监督职责 的情况汇报如下： 一、2023年年审会计师事务所基本情况 （一）会计师事务所基本情况 毕马威华振会计师事务所（特殊普通合伙）（以下简称毕马威华振）成立于 1992年8月，注册地址为北京市东城区东长安街1号东方广场东2座办公楼8层，首 席合伙人为邹俊。截至2023年12月31日，毕马威华振合伙人数量为234人，注册 会计师人数为1,121人，其中签署过证券服务业务审计报告的注册会计师超过260 人。 （二）聘任会计师事务所履行的程序 公司于2023年7月10 ...

华润博雅生物制药集团股份有限公司 自 2023 年 1 月 1 日 至 2023 年 12 月 31 日止年度财务报表 审计报告 毕马威华振审字第 2401844 号 华润博雅生物制药集团股份有限公司全体股东： 一、审计意见 我们审计了后附的华润博雅生物制药集团股份有限公司 (以下简称"华润博雅生物") 财务 报表，包括 2023 年 12 月 31 日的合并及母公司资产负债表，2023 年度的合并及母公司利润 表、合并及母公司现金流量表、合并及母公司股东权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照中华人民共和国财政部颁布的企业会计准 则 (以下简称"企业会计准则") 的规定编制，公允反映了华润博雅生物 2023 年 12 月 31 日的 合并及母公司财务状况以及 2023 年度的合并及母公司经营成果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则 (以下简称"审计准则") 的规定执行了审计工作。审计 报告的"注册会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按 照中国注册会计师职业道德守则，我们独立于华润博雅生物，并履行了职业道德方面 ...

中信证券股份有限公司 关于华润博雅生物制药集团股份有限公司 预计2024年度与关联方日常性关联交易额度的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为华润博雅 生物制药集团股份有限公司（以下简称"博雅生物"或"公司"）2020 年向特定对象 发行 A 股股票的保荐机构，根据《中华人民共和国公司法》（以下简称"《公司 法》"）《深圳证券交易所创业板股票上市规则》（以下简称"《股票上市规则》"） 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 （以下简称"《上市公司规范运作》"）等法律法规，对公司预计 2024 年度与关 联方日常性关联交易额度的事项发表核查意见如下： 一、关联交易概述 根据《公司法》《股票上市规则》《上市公司规范运作》的规定，公司控股 股东华润医药控股有限公司（以下简称"华润医药控股"）及其关联方视同为公司 的关联方，公司与华润医药控股及其关联方之间发生的交易构成关联交易，公司 预计 2024 年度与关联方日常性关联交易额度情况如下： （一）2023 年关联交易 1、2023 年日常关联交易 根据公司及控股子公司与华润医药控股及其关联方签订的 ...

华润博雅生物制药集团股份有限公司 内部控制审计报告 2023 年 12 月 31 日 内部控制审计报告 毕马威华振审字第 2403847 号 华润博雅生物制药集团股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了华润 博雅生物制药集团股份有限公司 (以下简称"华润博雅生物") 2023 年 12 月 31 日的财务报告 内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指 引》的规定，建立健全和有效实施内部控制，并评价其有效性是华润博雅生物董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见，并 对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的变化可 能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制审计结果推 测未来内部控制的有效性具有一定风险。 第 1 页，共 2 页 内部控制审计报告 (续) 毕马威华振审字第 ...